The latest figures on drug company spending on healthcare professionals have been released, with six out of 35 companies putting more than the $1 million each into funding event registrations, travel and accommodation costs, fees for service and consultancies.
Pfizer topped the list at nearly $1.9 million in total spending, followed by Boehringer Ingelheim at $1.38 million, while Bayer spent just over $1.2 million. The other companies with payments of more than $1 million were AstraZeneca, Novartis and BMS.
Analysis showed an average spending of $600,000 per company between 1 May and 31 October 2016, with the lowest spending by Vifor, at $20,410.
The figures were released as part of transparency reporting requirements of the Medicines Australia code of conduct.
The code requires consenting healthcare professionals to be named as recipients of funding, but around 40% of doctors chose to remain anonymous.
Pfizer’s faceless beneficiaries made up 52% of all payees, while 54% of healthcare professionals did not provide consent to Boehringer Ingelheim for their names to be reported.
The option to remain anonymous is being phased out however, and from this year all healthcare professionals receiving payments will named in reports.
To read the article by Felicity Nelson